Simple blood test could improve treatment for deadly childhood cancer

March 4, 2014

(Medical Xpress)—A simple blood test could pinpoint which children are unlikely to respond to treatment for a particularly aggressive form of neuroblastoma, according to a study published in the Journal of Clinical Oncology today.

The researchers – funded by Cancer Research UK and the Neuroblastoma Society – hope the test could help identify up to 20 per cent of children with 'ultra high-risk' forms of the disease, whose tends to stop responding to treatment and rarely survive for longer than two years.

Around 100 children are diagnosed with in the UK each year, usually in children aged five or under. Despite the numbers of children surviving neuroblastoma rising from around 40 per cent in the 1980s to 60 per cent today, the majority of children have a high-risk form of the disease which is still very hard to treat.

Study leader Professor Sue Burchill, from the School of Medicine at the University of Leeds, said: "The blood test we are developing can help identify children with the most aggressive form of the disease early on, so they can be offered other experimental treatments. This not only gives them the best chance of living longer, but will help speed up the development of much needed new treatments for this group of children."

Dr Guy Blanchard, a research trustee at The Neuroblastoma Society, said: "This new research shows that simple blood biomarkers can help identify at diagnosis a group of children with stage four neuroblastoma for whom new kinds of treatment are urgently needed.

"Because this study is a collaboration in several European countries the test has a better chance of being adopted more quickly and more widely. "

Lizzy Bremer was diagnosed with neuroblastoma in January 2013 after her parents Alex and Miriam noticed swelling in her stomach and on the side of her head. She was treated with chemotherapy and initially responded well, but scans later showed the cancer had spread. She died a few weeks later.

Her father, Alex, said: "I'll never forget the first night after she was diagnosed – Miriam and I were curled up in an armchair in the hospital, with every connotation of the diagnosis running through our heads. Your life turns upside down and things will never be the same again.

"When Lizzy started chemotherapy, there was some improvement at first and she even started walking for the first time, but around May, her temperature started to spike and we became increasingly nervous. When the scan results came back, it showed the cancer was rampant and we were transferred to palliative care. She passed away just two days after her second birthday in July – it was a wretched time and it is hard to think back on it coherently.

"Looking back, an early diagnosis of aggressive neuroblastoma is the only thing that could have helped Lizzy. She had months of chemotherapy which wasn't effective and if we had known she had the aggressive type of the disease, she could have been treated differently in that time. We welcome this research into the , which we hope might help other families in the future."

Kate Law, Cancer Research UK's director of clinical research, said: "Being able to spot in advance which children have more aggressive forms of neuroblastoma will help us develop treatments faster and get these children onto clinical trials sooner. Cancer Research UK is funding trials into a number of promising new treatments which we hope will give more options for with this devastating disease."

Explore further: New treatment hope for one of the deadliest childhood cancers

More information: Viprey et al. "Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma; a SIOPEN study," 2014 Journal of Clinical Oncology doi: 10.1200/JCO.2013.53.3604

Related Stories

New treatment hope for one of the deadliest childhood cancers

January 30, 2014
Cancer Research UK doctors have launched a new trial which offers a new type of molecular radiotherapy - never before tested in children - for one of the deadliest childhood cancers.

Redirecting our immune cells to help fight children's cancer

November 6, 2013
Immune cells, known as Natural Killer T cells, could be redirected to help fight the childhood cancer, neuroblastoma, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool ...

Beta-blockers may boost chemo effect in childhood cancer

May 22, 2013
Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, a type of children's cancer, according to a new study published in the British Journal of ...

New hope in the fight against childhood cancer

July 11, 2013
Cancer Research UK scientists at the University of Southampton are seeing positive results in a pre-clinical trial that could bring treatments for a particular aggressive form of childhood cancer closer to reality.

Improved screening means new targets for pediatric neuroblastoma therapies

March 1, 2014
Neuroblastoma is one of the most common and lethal types of childhood cancers. In a paper published online today in OncoTarget, a researcher at the University of Texas Health Science Center at San Antonio unveils the important ...

More than 33,000 childhood cancer survivors living in the UK

November 14, 2012
An estimated 33,000 long-term survivors of childhood cancer - the vast majority of whom are cured - will be living in the UK by the end of 2012, according to new figures from Cancer Research UK.

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.